BioStock: Qlife remains focused on planned merger with Chinese Hipro
Medical technology company Qlife's interim report for the third quarter of 2025 devotes great focus to the planned merger with Chinese Hipro Biotechnology. At the same time, the company has taken important steps in product development and regulatory processes, including the proprietary self-test Egoo PHE for phenylketonuria (PKU).
Read the full article at biostock.se:
Qlife remains focused on planned merger with Chinese Hipro
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/